Upon joining the study, you will be randomly assigned to one of two treatment groups. This random assignment is similar to flipping a coin and ensures fairness in the study.

One group will receive BMS-986504 (also called MRTX1719) combined with pembrolizumab and chemotherapy. The other group will receive a placebo (an inactive substance with no medication) combined with pembrolizumab and chemotherapy.

You will receive chemotherapy as part of your treatment. The specific chemotherapy medications may include paclitaxel, paclitaxel albumin-bound, carboplatin, cisplatin, or pemetrexed.

These medications will be given to you through a vein (intravenous administration).

The exact combination, dosage, frequency, and duration of chemotherapy will be determined based on your specific treatment plan.

You will receive pembrolizumab, which is a type of immunotherapy medication that helps your immune system fight cancer cells.

This medication will be given to you through a vein (intravenous administration).

The dosage, frequency, and duration will be determined according to the study protocol.

Depending on your assigned treatment group, you will receive either BMS-986504 (also known as MRTX1719) or a placebo.

BMS-986504 is an investigational medication being tested in this study. It may be given as a tablet by mouth (oral use) or through a vein (intravenous use).

If you receive the placebo, it will look identical to the active medication but contains no active ingredients.

The dosage, frequency, and duration will follow the study protocol.

Throughout the study, you will undergo regular monitoring to assess how the treatment is working and to check for any side effects.

This will include imaging scans to measure your tumor size according to RECIST v1.1 criteria, which is a standardized method for evaluating whether tumors are shrinking, staying the same, or growing.

Your doctor will monitor for progression free survival, which means the length of time during and after treatment that your cancer does not get worse.

Blood tests and other laboratory assessments will be performed to monitor your overall health and detect any abnormalities.

Your medical team will continuously monitor you for any adverse events, which are unwanted or harmful reactions that may occur during treatment.

This includes monitoring for both mild and serious side effects, as well as any reactions that may be related to the study medications.

If you experience side effects, your treatment may be adjusted, including dose interruptions, dose reductions, or discontinuation of the study medication if necessary.

All safety concerns will be documented and managed appropriately throughout your participation.

Your response to treatment will be evaluated regularly to determine if the cancer is responding to therapy.

The medical team will assess objective response, which means whether your tumor has shrunk significantly.

Disease control will be measured, which indicates whether the treatment is keeping the cancer from getting worse.

The time to objective response (how long it takes for the tumor to respond) and duration of response (how long the response lasts) will also be recorded.

After completing the active treatment phase, you will continue to be followed for long-term outcomes.

This includes monitoring your overall survival, which is the length of time you remain alive after starting treatment.

The study team will also track PFS2, which measures the time from starting treatment until your cancer progresses again after any subsequent therapy.

The study is expected to continue until August 2031, though your individual participation duration may vary.